Alpha Teknova, Inc. Form 8-K Summary
Business Context and Reporting Period
Alpha Teknova, Inc. (TKNO), a Delaware corporation, filed this Current Report on Form 8-K on May 10, 2022. The filing details the entry into a material definitive agreement to refinance and expand its existing credit facilities with MidCap Financial Trust.
Key Financial Metrics and Debt Structure
The Company entered into an Amended Credit Agreement increasing its total credit facility from $27.0 million to $57.135 million. The new structure includes:
- Amended Term Loan: $52.135 million senior secured term loan.
- Amended Revolver: $5.0 million working capital facility (expandable to $15.0 million).
- Initial Borrowing: $5.135 million borrowed immediately upon closing, in addition to the $12.0 million outstanding balance from the prior agreement.
- Interest Rates: Term Loan at one-month LIBOR + 6.45% (1.00% floor); Revolver at one-month LIBOR + 3.75% (1.00% floor).
- Maturity Date: May 1, 2027.
- Exit Fee: $0.6 million (5% of the initial $12.0 million borrowing from 2021).
Material Changes Versus Prior Period
The Amended Credit Agreement refinances the Credit Agreement dated March 26, 2021. Key changes include:
- Capacity Increase: Total facility capacity increased by $30.135 million.
- Staged Funding: Future tranches of the Term Loan are contingent on specific revenue and liquidity milestones:
- $5.0 million available October 31, 2022.
- $10.0 million available January 1, 2023 (subject to exceptions).
- $10.0 million available July 1, 2023 (contingent on $15.0 million trailing twelve-month "Clinical Solutions" revenue and $10.0 million liquidity).
- $10.0 million available January 1, 2024 (contingent on $19.0 million trailing twelve-month "Clinical Solutions" revenue and $15.0 million liquidity).
Guidance, Covenants, and Risks
The filing outlines significant financial covenants and restrictions:
- Financial Covenant: The Company must achieve trailing twelve-month net revenue of at least $42.5 million for the period ending December 31, 2022.
- Restrictions: The agreement restricts the Company's ability to pay dividends, make distributions, or repurchase capital stock.
- Collateral: Obligations are secured by first-priority security interests in all Company assets, excluding certain property.
- Events of Default: Include failure to pay principal/interest, covenant breaches, and incorrect representations. Default may trigger immediate acceleration of all loans.
Investor Verification Checklist
- Verify the Company's ability to meet the $42.5 million trailing twelve-month revenue covenant by December 31, 2022.
- Monitor progress toward "Clinical Solutions" revenue targets ($15.0 million and $19.0 million) required to unlock future loan tranches.
- Review the impact of the LIBOR floor (1.00%) on interest expense given current market rates.
- Assess the impact of dividend and share repurchase restrictions on shareholder returns.
- Confirm the availability of the Revolver based on the borrowing base formula (85% of domestic AR and 50% of eligible inventory).